Markets

Biohaven Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026

Oct 26, 2026 · 07:37 AM ET· updated 1h ago

Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. BHV-1420 is a novel

Why It Matters

Biohaven showed early lab results for a new kidney medicine. When companies share research like this, watch if doctors think it could actually help patients.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BHVN13.79

-0.09 (-0.65%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.